Viridian Therapeutics, Inc.\DE
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
VRDN$28.49-0.2%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · TSHR PROGRAM
TSHR PROGRAM
| • | VRDN-292: IND on track to initiate a phase 1 clinical trial in patients in Q4 2026 |
| • | VRDN-292 IND on track to support phase 1 clinical trial initiation in Q4 2026, starting in patients with Graves’ disease. |
| • | VRDN-292 is a potential best-in-class, half-life extended, monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), designed for subcutaneous delivery in an autoinjector with the potential to support extended dosing intervals for patient convenience. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.